MaxWell Biosystems speeds up industrialisation of drug screening device

The D-BSSE spin-off company develops cell imaging systems that reveal the function of neuronal networks in a dish. By raising Series A financing, the company will further industrialise and scale-up the production of its so called multiwell high-density microelectrode array (HD-MEA) plates. These devices enable customers in the pharmaceutical industry to run functional drug screenings at a higher throughput and ultimately contribute to an acceleration in the development of drugs targeting the brain.